Public Health Institutions, Clinical Research and Protection System of Patients’ Rights: An Impact Evaluation of Public Policy
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Public health institutions are involved in human experimentations, which is a specific phase of pharmaceutical industry’s production process. These medical centers collect clinical evidence about experimental treatments and, at the same time, they have to guarantee patients’ safety through appropriate Institutional Review Boards. Taking human experimentation into account, this work aims at estimating a public policy designed to reduce transaction costs that are related to the protection system of patients’ rights, with both a normative and positive approach. On the one hand, considering a sample of European countries as counterfactual, an empirical analysis is performed in order to estimate the impact of a national law aimed at harmonizing the procedure to obtain opinions on clinical trials. On the other hand, an alternative law, which might be able to favor the exchange between pharmaceutical companies and patients, is proposed.
- Adobor, H. (2011). Ethical issues in outsourcing: the case of contract medical research and the global pharmaceutical industry. Journal of Business Ethics. doi:10.1007/s10551-011-0964-0.
- Arrow, K. J. (1963). Uncertainty and the welfare economics of medical care. The American Economic Review, 3(5), 941–973.
- Arrow, K.J. (1969). “The Organization of Economic Activity: Issues pertinent to the choice of market versus nonmarket allocation” in The Analysis and Evaluation of Public Expenditure: The PPB System. Vol. 1, U.S. Joint Economic Committee, 91st Congress, 1st Session, 59–73. Washington, DC: U.S. Government Printing Office.
- Bodenheimer, T. (2000). Uneasy alliance: clinical investigators and the pharmaceutical industry. Health Policy Report, 342(20), 1539–1544.
- Calabresi, G. (1969). Reflection on medical experimentation in human. Daedalus, 98(2), 387–405.
- Coase, R. H. (1937). The nature of the firm. Economica, 4(16), 386–405. CrossRef
- Coase, R. H. (1960). The problem of social cost. Journal of Law and Economics, 3(1), 1–44. CrossRef
- Coase, R. H. (1988). The nature of the firm: influence. Journal of Law, Economics, and Organization, 4(1), 33–47.
- Cooter, R., Ulen, T. (2000). Law and economics. Addison Wesley Longman, third edition.
- de Figueiredo, R. J. P., Jr. (2010). Institutions, politics, and non-market strategy. California Management Review, 52(2), 123–131. CrossRef
- Les Entreprises du Médicament, (2008). L’industrie du médicament en France, réalités économiques, Edition 2008.
- Hilbe, J. M. (2011). Negative binomial regression. New York: Cambridge University Press. CrossRef
- Ippoliti, R. (2010). The market of human experimentation. European Journal of Law and Economics. doi:10.1007/s10657-010-9190-y.
- Madhu, D. (2007). The procedure for the ethical review of protocols for clinical research projects in the European Union. report on the structure and function of research ethics committees across Europe. A Pharmaceutical Physician, 18(1), 24–25.
- Smith, A. (2007). The procedure for the ethical review of protocols for clinical research projects in the European Union. A special Issue of the International Journal of Pharmaceutical Medicine. CRFocus Review, 18(3), 18.
- Williamson, O. E. (1979). Transaction cost economics: the governance of contractual relations. Journal of Law and Economics, 22(2), 233–261. CrossRef
- Williamson, O. E. (1996). The mechanisms of governance. New York: Oxford University Press.
- Williamson, O. E. (2002). The theory of the firm as governance structure: from choice to contract. Journal of Economic Perspectives, 16(3), 171–195. CrossRef
- Williamson, O. E. (2008). Corporate Boards of Directors: in principle and in practice. Journal of Law, Economics, and Organization, 24(2), 247–272. CrossRef
- Williamson, O. E. (2009). Transaction cost economics: the natural progression. Nobel Prize Lecture, December, 8, 2009.
- Public Health Institutions, Clinical Research and Protection System of Patients’ Rights: An Impact Evaluation of Public Policy
Public Organization Review
Volume 14, Issue 2 , pp 109-125
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Public policy
- Public health organizations
- Transaction costs
- International Review Boards (IRB)
- Clinical research
- I18 (Government Policy Regulation; Public Health)
- L51 (Economics of Regulation)
- Industry Sectors